MAB-B-2M

MAB-B-2M is a monoclonal antibody currently in preclinical development by MAB DESIGNS. It specifically targets Beta-2 microglobulin (β-2M), which is the light chain component of the Major Histocompatibility Complex (MHC) class I molecules present on the surface of nearly all nucleated cells. Although the specific therapeutic indications have not been publicly detailed by the company, antibodies against β-2M are generally explored for the treatment of hematological malignancies like multiple myeloma, where β-2M is often overexpressed, or for dialysis-related amyloidosis. The antibody is designed to bind to cells presenting the β2M/MHC I complex, potentially triggering immune-mediated cell death or interfering with MHC I-mediated signaling.

Other names

anti-β2MB-2MB2MB 2MBeta-2 microglobulin monoclonal antibodyBeta2 microglobulin monoclonal antibodyBeta 2 microglobulin monoclonal antibody